Table 3. Crude and adjusted metaregression analyses of change in 6-month cumulative incidence of antiretroviral treatment initiation (CI-ART) after ART eligibility guideline expansion to CD4 ≤ 350 and CD4 ≤ 500.
| Guideline expansion to CD4 ≤ 350a | Guideline expansion to CD4 ≤ 500a | ||||
|---|---|---|---|---|---|
|
Site characteristic |
Unit |
Crude Beta (95% CI) |
Adjusteda Beta (95% CI) |
Crude Beta (95% CI) |
Adjusteda Beta (95% CI) |
| Baseline 6-month CI-ART | 10 pp decrease | 3.8 (2.3–5.3) | 3.9 (2.4–5.4) | 4.8 (3.4–6.1) | 5.3 (3.9–6.7) |
| Baseline median CD4 at enrollment | 10 cell/μl increase | 0.4 (0.2–0.7) | 0.0 (−0.3–0.3) | ||
| Median age at enrollment | 1-year increase | −0.5 (−1.1–0.2) | 0.0 (−0.6–0.6) | ||
| Proportion female | 1-pp increase | −0.1 (−0.2–0.1) | 0.0 (−0.1–0.1) | ||
| Cohort size | 1-log increase | 1.0 (−1.0–3.0) | 2.6 (0.8–4.5) | 0.0 (−1.9–1.9) | 2.0 (0.3–3.7) |
| Setting | Urban | 0.6 (−4.0–5.3) | −2.7 (−7.0–1.6) | ||
| Rural | Reference | Reference | |||
| Unknown | −3.3 (−9.0–2.4) | 1.1 (−3.9–6.2) | |||
a The model was also adjusted for ART eligibility concurrently expanded to encompass all individuals with tuberculosis or pregnancy.